Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the latest. Feel free to point out in the comments. This article is only for the introduction of medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.
June 12,RECORNA (Guangzhou) Biotechnology Co., Ltd.AndStarna Therapeutics (Suzhou) Co., Ltd.Announced the official signing of a strategic cooperation agreement,Jointly Explore the Research and Application of RNA Gene Editing Drugs in the Field of Pulmonary Diseases.
This collaboration will utilize Starna Therapeutics' self-developedSTAR LNP Delivery TechnologyPlatform, RECORNA is based onMINIC RNA Platform Gene Editing DrugsPrecise delivery to the lungs. Unlike traditional liver-enriched LNP systems,STAR LNP technology can efficiently deliver small nucleic acids to the lungs.`, achieving efficient and precise gene editing while avoiding off-target toxicity.`MINIC RNA Editing Platform Focuses on Precise Single-Point Editing at the RNA Level Using Small Nucleotide Drugs, SpiritThe reversible regulation of gene expression and function can achieve various controls of RNA, demonstrating safer and more diversified characteristics.Both parties plan to jointly screen preclinical candidate molecules (PCC) and advance them to the clinical development stage.。
RecoRNA CEO Xin RongStarna Therapeutics' lung-targeted LNP can achieve precise delivery while balancing effectiveness and safety. We believe that, with the support of Starna's delivery system, we can expand more treatment pipelines for lung diseases based on RNA editing technology.Starna Therapeutics CEO Hu RongkuanDr. stated: "RecoRNA's RNA editing technology utilizing endogenous ADAR proteins is highly flexible and safe, capable of repairing and optimizing protein sequences and functions without altering the genomic sequence. We believe that with the support of both parties' technologies, we can jointly provide innovative solutions for lung diseases."”RECORNA is a small nucleic acid drug research and development company that develops innovative drugs targeting health threats for which there are currently no effective conventional treatments, utilizing technology platforms such as RNA editing. It is committed to addressing unmet clinical needs, including cardiovascular diseases, neurodegenerative disorders, and anti-aging solutions. Relying on the technology transfer from the School of Life Sciences at Sun Yat-sen University, RECORNA has established an independent RNA editing platform capable of repairing and optimizing protein sequences and functions without permanently altering the genome. The company, located in the BeiGene Innovation Center on Guangzhou Bio Island, has built an early-stage R&D platform, including laboratory facilities for drug discovery, biological validation, and delivery system development.Starna Therapeutics was founded in August 2021. The company focuses on extrahepatic targeted delivery technology and is committed to developing innovative drugs centered on RNA to address unmet clinical needs. The company has established a research, development, and pilot production base of over 4,000 square meters, creating capabilities around chemistry, mRNA, andLNP FormulationThe core industrial chain, effectively overcoming the key difficulties in RNA drug development. The company has successively obtained financing of several hundred million yuan participated by multiple well-known funds, and has laid out an extensive R&D pipeline in mRNA vaccines and innovative therapies, among which...Respiratory Syncytial VirusThe mRNA vaccine STR-V003 has received FDA approval for clinical trials and is expected to commence clinical trials in 2024.Source of the article:Starna therapeutics
